Shots:
- Sanofi has reported P-IIb (AIRCULES), P-IIa (DUET) PoC & P-IIb (VELVET) data assessing lunsekimig (SC) in adults with mod. to sev. asthma, CRSwNP, & in mod. to sev. atopic dermatitis, respectively
- In AIRCULES, lunsekimig met 1 & 2EPs, reducing exacerbations & improving lung fuction as measured by pre-BD FEV1 vs PBO, while in DUET it met 1EP (nasal polyp score) & key 2EP, improving nasal congestion/obstruction & LMK-CT scores vs PBO at Wk. 24
- In VELVET, lunsekimig did not meet its 1EP of % change in EASI score but showed improvements in key 2EPs for skin clearance, incl. EASI-75 & vIGA-AD 0/1; data to be presented at a future conference
Ref: Sanofi | Image: Sanofi |Press Release
Related News: Regeneron and Sanofi Report MHLW’s Approval of Dupixent to Treat Bullous Pemphigoid
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
